KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
PITTSBURGH, November 18, 2024 BUSINESS WIRE KaliVir Immunotherapeutics, Inc. , a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the expansion of its patent portfolio with the addition of three new patents recently issued by the United States Patent and Trademark Office. The patents (No. 11,963,990, 12,016,893 and 12,036,257) cover novel modifications to enhance tumor targeting, immune modulation and systemic delivery of oncolytic viruses. "With the granting of these patents, we believe we are garnering one of the most robust oncolytic viral immunotherapy portfolios," said Steve Thorne, PhD, Chief Scientific Officer and co-founder of KaliVir Immunotherapeutics. "The addition of these patents better protect our platform, strengthen our patent portfolio and underscore our commitment to innovation in cancer immunotherapy." The newly patented technologies are being applied to KaliVir's pipeline of
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Optical Imaging Agent Market Expected to Expand at 8.1% CAGR, Reaching US$ 3,533.2 Million by 2034 | Fact.MR Report [Yahoo! Finance]Yahoo! Finance
- Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management [Yahoo! Finance]Yahoo! Finance
- Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure ManagementPR Newswire
- Should Value Investors Buy Astellas Pharma (ALPMY) Stock? [Yahoo! Finance]Yahoo! Finance
- Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday [Yahoo! Finance]Yahoo! Finance